N Kluger1, W Jacot2, E Frouin3, V Rigau3, S Poujol4, O Dereure1, B Guillot1, G Romieu2, D Bessis5. 1. University of Montpellier 1, Montpellier; Department of Dermatology, Saint-Eloi Hospital, Montpellier. 2. University of Montpellier 1, Montpellier; Department of Medical Oncology, CRLC Val d'Aurelle, Montpellier. 3. University of Montpellier 1, Montpellier; Department of Pathology, Hôpital Gui-de-Chauliac, Montpellier. 4. University of Montpellier 1, Montpellier; Oncopharmacology Department, CRLC Val d'Aurelle, Montpellier, France. 5. University of Montpellier 1, Montpellier; Department of Dermatology, Saint-Eloi Hospital, Montpellier. Electronic address: d-bessis@chu-montpellier.fr.
Abstract
BACKGROUND: To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment. PATIENTS AND METHODS: Women treated for breast cancer by a sequential adjuvant FEC and docetaxel regimen who developed permanent alopecia diagnosed between 2007 and 2011 were identified from the Department of Dermatology (Saint-Eloi Hospital, Montpellier, France) and the Department of Medical Oncology (CRLC Val d'Aurelle, Montpellier, France). Data were collected regarding demographics, type of cancer, delay of onset after chemotherapy, Dermatology Life Quality Index (DLQI), clinical description of the lesions, scalp biopsies, laboratory explorations investigating steroid hormonal, iron, zinc and thyroid status, therapy and outcome. RESULTS: Twenty white Caucasian females were included. Hair loss presented with a moderate or intense androgenetic-like pattern of scalp alopecia. Biopsy specimen examinations were normal or displayed the androgenetic-like pattern. Laboratory explorations ruled out iron or zinc deficiency and thyroid disorders and confirmed hormonal menopause without hyperandrogenism. The overall mean DLQI score reflected the distressing psychological consequences in the patients' lives. No spontaneous regrowth of the scalp hair was noted. Treatment including vitamins, minoxidil, psoralen and ultraviolet A therapy and spironolactone proved to be ineffective. CONCLUSION: Permanent and severe alopecia is a newly reported complication of the FEC 100-docetaxel breast cancer regimen.
BACKGROUND: To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment. PATIENTS AND METHODS: Women treated for breast cancer by a sequential adjuvant FEC and docetaxel regimen who developed permanent alopecia diagnosed between 2007 and 2011 were identified from the Department of Dermatology (Saint-Eloi Hospital, Montpellier, France) and the Department of Medical Oncology (CRLC Val d'Aurelle, Montpellier, France). Data were collected regarding demographics, type of cancer, delay of onset after chemotherapy, Dermatology Life Quality Index (DLQI), clinical description of the lesions, scalp biopsies, laboratory explorations investigating steroid hormonal, iron, zinc and thyroid status, therapy and outcome. RESULTS: Twenty white Caucasian females were included. Hair loss presented with a moderate or intense androgenetic-like pattern of scalp alopecia. Biopsy specimen examinations were normal or displayed the androgenetic-like pattern. Laboratory explorations ruled out iron or zinc deficiency and thyroid disorders and confirmed hormonal menopause without hyperandrogenism. The overall mean DLQI score reflected the distressing psychological consequences in the patients' lives. No spontaneous regrowth of the scalp hair was noted. Treatment including vitamins, minoxidil, psoralen and ultraviolet A therapy and spironolactone proved to be ineffective. CONCLUSION: Permanent and severe alopecia is a newly reported complication of the FEC 100-docetaxelbreast cancer regimen.
Authors: Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture Journal: Eur J Dermatol Date: 2016-10-01 Impact factor: 3.328
Authors: Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture Journal: Breast Cancer Res Treat Date: 2018-11-22 Impact factor: 4.872
Authors: Azael Freites-Martinez; Jerry Shapiro; Corina van den Hurk; Shari Goldfarb; Joaquin J Jimenez; Anthony M Rossi; Ralf Paus; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2018-04-14 Impact factor: 11.527
Authors: Danbee Kang; Im-Ryung Kim; Yeon Hee Park; Young Hyuck Im; Di Zhao; Eliseo Guallar; Jin Seok Ahn; Juhee Cho Journal: Support Care Cancer Date: 2019-07-23 Impact factor: 3.603
Authors: Gregory S Phillips; Morgan E Freret; Danielle Novetsky Friedman; Sabrina Trelles; Oluwaseun Kukoyi; Azael Freites-Martinez; Robin H Unger; Joseph J Disa; Leonard H Wexler; Christopher L Tinkle; James G Mechalakos; Stephen W Dusza; Kathryn Beal; Suzanne L Wolden; Mario E Lacouture Journal: JAMA Dermatol Date: 2020-09-01 Impact factor: 10.282